FDA Grants Orphan Drug Designation (ODD) Status to NeoImmuneTech’s NT-I7 for Advanced Pancreatic Cancer Treatment

Pancreatic cancer has the highest mortality rate of all major cancers with only a 3% relative-survival-rate at 5-years for the advanced form. [1], [2] Pancreatic tumors are highly resistant to chemotherapy and radiation and there are limited treatment options[2] FDA ODD designation…